Chordoma Disease Market Research Report - Forecast to 2027

Global Chordoma Disease Market Research Report: By Diagnosis (Biopsy, Imaging, Blood Tests), Treatment (Chemotherapy, Radiation Therapy, Cryosurgery, Surgery, Targeted Therapy), End-User (Hospital, Clinic, Cancer Care Centers) – Global Forecast Till 2027

ID: MRFR/Pharma/4328-HCR | February 2021 | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Chordoma is a rare type of primary bone cancer that is typically malignant in nature. This type of tumor occurs mostly at the skull base or along the spine. These tumors are formed from small fragments of embryonic cells that accumulate into the disks of the spinal column. The prevalence is found to be twice in men in comparison with women. Moreover, most of the tumor cases occur between the age group of 50 to 70 years.


According to the American Cancer Society, over 40% of primary bone cancers are chondrosarcomas. The maximum prevalence is given to osteosarcomas (28%), followed by chordomas (10%), Ewing tumors (8%), and malignant fibrous histiocytoma (4%). About two out of five chordomas (40%) propagate in the skull region, while the rest develop in the bones of the spine.


The preferred surgical treatment for chordomas of the skull base is Endoscopic Endonasal Approach (EEA) developed by UPMC. This minimally invasive technique uses nasal cavities as a corridor to reach the inoperable tumors. The benefits of EEA surgeries include no incisions to heal, no disfigurement, and faster recovery.


The increasing occurrence of bone cancer along with growing government initiatives for bone cancer awareness and aging population globally are the major factors expected to fuel the global chordoma disease market over the forecast period.


Global Market for the Chordoma Disease is expected to grow at a CAGR of approximately 6.8% during 2017 to 2023.


Intended Audience



  • Chordoma drug manufacturers

  • Chordoma drug suppliers

  • Biotechnology companies

  • Government institutes

  • Research and development companies

  • Academic medical centers and universities

  • Research and consulting firms

  • Venture capital firms


Segmentation


The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.


On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.


On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.


On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.


Research Methodology


 chordoma disease market


Sources: Annual reports, Press release, White paper, and Company presentation


Regional Analysis                     


The global chordoma disease market consists of four regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.


The Americas region accounted for the largest market share of the global chordoma disease market owing to the high prevalence of bone cancer in the region and aging population, along with high favorable reimbursement policies in the region. As per the American Cancer Society in 2017, about 3,260 people are projected to be diagnosed with primary bone cancer in the U.S. (1,820 men and boys and 1,440 women and girls).


The European chordoma disease market is anticipated to emerge as the second largest market owing to the development of the pharmaceutical and medical industries. According to the Cancer Research U.K. organization in 2014, about 580 new cases of bone sarcoma were found in the U.K.


The Asia Pacific region is expected to grow rapidly during the forecast period owing to less awareness regarding bone cancer among the population and less availability of effective treatment option for bone cancer in the region. For instance, in September 2016, Dr. Reddy's Laboratories entered into a strategic collaboration with Amgen for marketing and distributing Prolia (denosumab), Vectibix (panitumumab), and Xgeva (denosumab) in India.


The Middle Eastern region is expected to grow at a steady pace owing to factors such as rising R&D activities in the healthcare sector and extensive development of the healthcare infrastructure.


Key Players


Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.



Frequently Asked Questions (FAQ) :


Chordoma Disease Market is projected to grow at a 6.8 % CAGR between 2020-2027..

The Americas is expected to lead the Chordoma Disease Market.

Growing government initiatives and rising prevalence of bone cancer are adding market growth.

High prevalence of chondroid chordomas may limit market growth.

Different strategies used by market players to create a dominance in the Chordoma Disease Market include mergers and acquisitions, collaborations, product developments and others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Disease Indication Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chordoma Treatment Market, by Diagnosis

6.1 Introduction

6.2 Biopsy

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Imaging

6.3.1 Market Estimates & Forecast, 2020–2027

6.3.2 X-Ray

6.3.2.1 Market Estimates & Forecast, 2020–2027

6.3.3 Magnetic Resonance Imaging (MRI),

6.3.3.1 Market Estimates & Forecast, 2020–2027

6.3.4 Computed Tomography (CT) Scan,

6.3.4.1 Market Estimates & Forecast, 2020–2027

6.3.5 Positron Emission Tomography (PET) Scanning

6.3.5.1 Market Estimates & Forecast, 2020–2027

6.3.6 Bone Scan

6.3.6.1 Market Estimates & Forecast, 2020–2027

6.4 Blood Tests

6.4.1 Market Estimates & Forecast, 2020–2027

6.5 Others

Chapter 7. Global Chordoma Treatment Market, by Treatment

7.1 Introduction

7.2 Chemotherapy

7.2.1 Market Estimates & Forecast, 2020–2027

7.2.2 Methotrexate

7.2.2.1 Market Estimates & Forecast, 2020–2027

7.2.3 Doxorubicin

7.2.3.1 Market Estimates & Forecast, 2020–2027

7.2.4 Others

7.3 Radiation Therapy

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Cryosurgery

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Surgical Treatments

7.5.1 Market Estimates & Forecast, 2020–2027

7.5.2 Radical Resections

7.5.2.1 Market Estimates & Forecast, 2020–2027

7.5.3 Sacral Chordoma

7.5.3.1 Market Estimates & Forecast, 2020–2027

7.5.4 Spinal Chordoma

7.5.4.1 Market Estimates & Forecast, 2020–2027

7.5.5 Skull Base Chordoma

7.5.5.1 Market Estimates & Forecast, 2020–2027

7.5.6 Others

7.6 Radiosurgery

7.6.1 Market Estimates & Forecast, 2020–2027

7.7 Targeted Therapy

7.7.1 Market Estimates & Forecast, 2020–2027

7.7.2 Bevacizumab

7.7.2.1 Market Estimates & Forecast, 2020–2027

7.7.3 Erlotinib

7.7.3.1 Market Estimates & Forecast, 2020–2027

7.7.4 Others

7.8 Others

Chapter 8. Global Chordoma Treatment Market, by End-User

8.1 Introduction

8.2 Hospital

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Clinic

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Cancer Care Centers

8.4.1 Market Estimates & Forecast, 2020–2027

8.5 Others

Chapter. 9 Global Chordoma Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K.

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11 Company Profiles

11.1 GlaxoSmithKline plc

11.1.1 Company Overview

11.1.2 Segment Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Pfizer, Inc.

11.2.1 Company Overview

11.2.2 Segment Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Merck & Co., Inc.

11.3.1 Company Overview

11.3.2 Segment Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Sanofi Pasteur SA

11.4.1 Company Overview

11.4.2 Segment/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Astellas Pharma Inc.

11.5.1 Company Overview

11.5.2 Segment Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 CSL Limited

11.6.1 Company Overview

11.6.2 Segment Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Emergent BioSolutions, Inc.

11.7.1 Overview

11.7.2 Segment Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Johnson & Johnson

11.8.1 Company Overview

11.8.2 Segment/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.8.5 SWOT Analysis

11.9 MedImmune, LLC

11.9.1 Company Overview

11.9.2 Segment Overview

11.9.3 Financial overview

11.9.4 Key Developments

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Chordoma treatment Industry Synopsis, 2020–2027

Table 2 Chordoma Treatment Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Chordoma Treatment Market, by Region, 2020–2027, (USD Million)

Table 4 Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 5 Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 6 Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 7 North America Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 8 North America Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 10 U.S. Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 11 U.S. Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 12 U.S. Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 Canada Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 16 South America Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 17 South America Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 20 Europe Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 23 Western Europe Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Eastern Europe Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia Pacific Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 29 Asia Pacific Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

Table 31 The Middle East & Africa Chordoma Treatment Market, by Diagnosis, 2020–2027, (USD Million)

Table 32 The Middle East & Africa Chordoma Treatment Market, by Treatment, 2020–2027, (USD Million)

Table 33 The Middle East & Africa Chordoma Treatment Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Chordoma Treatment Market

Figure 3 Segmentation Market Dynamics for Chordoma Treatment Market

Figure 4 Global Chordoma Treatment Market Share, by Diagnosis 2020

Figure 5 Global Chordoma Treatment Market Share, by Treatment 2020

Figure 6 Global Chordoma Treatment Market Share, by End-User, 2020

Figure 7 Global Chordoma Treatment Market Share, by Region, 2020

Figure 8 North America Chordoma Treatment Market Share, by Country, 2020

Figure 9 Europe Chordoma Treatment Market Share, by Country, 2020

Figure 10 Asia Pacific Chordoma Treatment Market Share, by Country, 2020

Figure 11 The Middle East & Africa Chordoma Treatment Market Share, by Country, 2020

Figure 12 Global Chordoma Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 GlaxoSmithKline plc: Key Financials

Figure 14 GlaxoSmithKline plc: Segmental Revenue

Figure 15 GlaxoSmithKline plc: Geographical Revenue

Figure 16 Pfizer, Inc.: Key Financials

Figure 17 Pfizer, Inc.: Segmental Revenue

Figure 18 Pfizer, Inc.: Geographical Revenue

Figure 19 Merck & Co., Inc.: Key Financials

Figure 20 Merck & Co., Inc.: Segmental Revenue

Figure 21 Merck & Co., Inc.: Geographical Revenue

Figure 22 Sanofi Pasteur SA: Key Financials

Figure 23 Sanofi Pasteur SA: Segmental Revenue

Figure 24 Sanofi Pasteur SA: Geographical Revenue

Figure 25 Astellas Pharma Inc.: Key Financials

Figure 26 Astellas Pharma Inc.: Segmental Revenue

Figure 27 Astellas Pharma Inc.: Geographical Revenue

Figure 28 CSL Limited: Key Financials

Figure 29 CSL Limited: Segmental Revenue

Figure 30 CSL Limited: Geographical Revenue

Figure 31 Emergent BioSolutions, Inc.: Key Financials

Figure 32 Emergent BioSolutions, Inc.: Segmental Revenue

Figure 33 Emergent BioSolutions, Inc.: Geographical Revenue

Figure 34 Johnson & Johnson: Key Financials

Figure 35 Johnson & Johnson: Segmental Revenue

Figure 36 Johnson & Johnson: Geographical Revenue

Figure 37 MedImmune, LLC: Key Financials

Figure 38 MedImmune, LLC: Segmental Revenue

Figure 39 MedImmune, LLC: Geographical Revenue